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Abstract
Long-term mechanical ventilation is a well-established treat-
ment for chronic hypercapnic respiratory failure (CHRF). It is 
aimed at improving CHRF-related symptoms, health-related 
quality of life, survival, and decreasing hospital admissions. 
In Switzerland, long-term mechanical ventilation has been 
increasingly used since the 1980s in hospital and home care 
settings. Over the years, its application has considerably ex-
panded with accumulating evidence of beneficial effects in 
a broad range of conditions associated with CHRF. Most fre-
quent indications for long-term mechanical ventilation are 
chronic obstructive pulmonary disease, obesity hypoventila-
tion syndrome, neuromuscular and chest wall diseases. In 
the current consensus document, the Special Interest Group 
of the Swiss Society of Pulmonology reviews the most recent 
scientific literature on long-term mechanical ventilation and 
provides recommendations adapted to the particular set-
ting of the Swiss healthcare system with a focus on the prac-
tice of non-invasive and invasive home ventilation in adults.
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Abbreviation used in this paper
ABG Arterial blood gases LVEF Left ventricular ejection fraction
aPCV Assisted pressure control ventilation MIE Mechanical insufflation/exsufflation device
AEHRF Acute episode of hypercapnic respiratory failure MIP Mouth maximal inspiratory pressure
AHI Apnea-hypopnea index mm Hg Millimeters of mercury
ALS Amyotrophic lateral sclerosis MPV Mouthpiece ventilation
ASV Adaptive servo ventilation NIV Non-invasive ventilation
AVAPS Average volume-assured pressure support NMD Neuromuscular diseases
BMI Body mass index ODI  Oxygen desaturation index
BURR Back-up respiratory rate OHS  Obesity hypoventilation syndrome
CHRF Chronic hypercapnic respiratory failure OLD Obstructive lung diseases
COPD Chronic obstructive pulmonary disease OSA Obstructive sleep apnea 
CPAP Continuous positive airway pressure PCV Pressure controlled ventilation
CSA Central sleep apnea PEEP Positive end-expiratory pressure
CSB Cheyne Stokes breathing PEEPi Intrinsic positive end-expiratory pressure
DMD Duchenne’s muscular dystrophy PIF Peak inspiratory flow
EPAP Expiratory positive airway pressure PS Pressure support (=IPAP-EPAP)
ETCO2 End-tidal partial pressure of CO2 PSG Polysomnography
FiO2 Inspired fraction of oxygen PSV Pressure support ventilation
GLS Geneva Lake Study PtcCO2 Transcutaneous estimation of PaCO2
HCW Health care worker QoL Quality of life
HMV Home mechanical ventilation RCT Randomized controlled trial
HOT Home oxygen therapy RLD Restrictive lung diseases
HRQL Health related quality of life SNIP Sniff nasal inspiratory pressure
ICU Intensive care unit SRBD Sleep-related breathing disorders
ILD Interstitial lung disorders TPPV Positive pressure ventilation via tracheostomy
IPAP Inspiratory positive airway pressure VC Vital capacity
IVAPS Intelligent volume-assured pressure support VAC Volume assisted ventilation
kPa Kilopascal VCV Volume controlled ventilation
LTOT Long-term oxygen therapy VT Tidal volume
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1. Introduction
Home non-invasive positive pressure ventilation 
(NIV) appeared in Switzerland in the mid-80s, as in most 
neighboring countries, shortly after the publication by 
Sullivan et al. [1] of the successful treatment of obstruc-
tive sleep apnea (OSA) by continuous positive airway 
pressure via a nasal mask (CPAP). In 1990, 24 patients 
were ventilated non-invasively in Switzerland [2]. Al-
though there are no official national statistics, a reason-
able estimation of the trend in prevalence of home NIV 
can be derived from 2 surveys performed in the Cantons 
of Geneva and Vaud (Geneva Lake Study; GLS) [3, 4]. Be-
tween 2000 and 2018, NIV users increased from 15/105 to 
38/105 inhabitants. To put these figures in perspective, 
use of CPAP in the same area (≈ 20,000 patients treated) 
is presently 40 times higher (1,552/105 inhabitants) [5]. 
Conversely, the number of patients on invasive ventila-
tion via tracheostomy remains marginal. These figures 
are close to those reported by European countries with a 
national registry: 47/105 inhabitants in Norway (Septem-
ber 2019, Norwegian National registry for long-term ven-
tilation), 33/105 inhabitants in Sweden (2018, Swedevox), 
and 39.5/105 inhabitants in Finland [6].
1.1. Methodology
The Swiss Society of Pulmonology (SSP) and the Swiss 
Society of Pediatric Pulmonology have previously pub-
lished recommendations on home mechanical ventila-
tion (HMV; 1996, 2006, 2010) [7–9]. This narrative re-
view includes the most recent recommendations of our 
group based on an extensive review of the medical litera-
ture through PubMed over the past 10 years, of other na-
tional guidelines [10–15], and of the specifics of care for 
long-term HMV in Switzerland. The final text was dis-
cussed thoroughly among the members of the Special In-
terest Group on HMV (SIG) to reach a consensus. 
This text focuses on HMV provided at home or in 
long-term care institutions and will cover indications, 
modalities and follow-up of patients on HMV. We will 
also comment on the use of mechanical insufflation/ex-
sufflation (MIE) devices, and their indication. This docu-
ment does not cover NIV in the acute care setting (emer-
gency ward, ICU, acute-care hospital wards) or the pedi-
atric population.
1.2. Indications for Long-Term Non-Invasive 
Ventilation
Indications for long-term NIV, which have evolved 
over the past 30 years, are summarized in Figure 1 and 
Table 1 [16]. The obesity-hypoventilation syndrome 
(OHS), chronic obstructive pulmonary diseases (COPD; 
including overlap syndrome), and neuromuscular and 
chest wall diseases (CWD) are presently the most fre-
quent indications for HMV. Although practices may vary 
from one Canton (region) or University Hospital to an-
other, trends follow the practices of other European 
countries. 
1.3. General Comments and Caveats
Although patients on long-term home NIV are a very 
heterogeneous population, they share a certain number 
of characteristics:
• They often have several comorbidities (most often car-
diovascular, cerebro-vascular or neurological disor-
ders) [4]. 
• They are increasingly overweight or obese [4, 17].
• Mean age of this population is increasing [4, 17].
• Mild or moderate cognitive impairment may coexist 
with the underlying pathology (i.e., severe COPD [18, 
19], advanced amyotrophic lateral sclerosis (ALS) [20–
22], some chronic neuromuscular diseases (NMD), 
very old subjects, sequelae of acute or chronic cerebral 
traumatic or non-traumatic lesions...).
• They may represent a considerable burden for care 
providers.
The follow-up of patients on NIV must therefore deal 
with all these aspects, in close collaboration with primary 
care physicians and the local healthcare network. Because 
many of the disorders leading to chronic hypercapnic re-
spiratory failure (CHRF) are rare, the pulmonologist is 
often referred to as an expert and healthcare coordinator. 
1.4. Choice of Ventilators and Ventilator Modes
Table 2 summarizes the ventilator modes most com-
monly used for long-term NIV [23]. In long-term NIV, 
bi-level positive pressure support ventilation in sponta-
neous/timed mode (PSV-ST; Table 2) is presently the 
most commonly used mode in clinical practice. These 
recommendations will therefore focus on this mode and 
will comment on the specifics of other ventilator settings 
in certain indications. A reminder of the basic settings for 
PSV-ST is provided in Figures 2 and 3. The reader is also 
provided with ventilator settings used in Swiss publica-
tions as an indication of possible settings (online supple-
ment; see www.karger.com/doi/10.1159/000510086 for 
all online suppl. material) [4, 24]. Volumetric ventilation 
is mainly considered in case of failure of PSV or pressure-
controlled ventilation (PCV), in some NMD, in very se-
vere OHS, and in difficult cases of patient ventilator 
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asynchrony (e.g., paradoxical adduction of vocal cords in 
ALS) [25]. Volumetric ventilators have been considered 
historically as “default devices” in invasive ventilation 
(i.e., ventilation by tracheostomy), although invasive 
ventilation with PSV and appropriate humidification is 
clearly feasible if appropriate humidification is ensured 
[26].
A distinction between ventilators for home care must 
be made between “Life-support devices” (with EU certi-
fication, compatibility with simple or double respiratory 
circuit and non-rebreathing expiratory valve, built-in 
battery of > 8 h of autonomy and “full range” of alarms 
including: electrical failure, patient disconnection, high 
non-intentional leaks, changes in minute ventilation), 
“Life-sustaining devices” (built-in battery not fulfilling 
life support criteria, basic range of alarms) and other 
home care devices (no built-in battery, minimal or no 
alarms) [27]. Ventilators with a built-in battery are the 
recommended devices for patients requiring more than 
16 h/day of ventilatory support. For these patients (see 
section 7.1. on dependent patients), prescription of a sec-
ond ventilator is recommended. 
These recommendations will not address the issue of 
automated modes (Table 2). Over the past 15 years, a mul-
titude of automated ventilator modes have been proposed 
by the industry. This trend started with volume-targeted 
devices (AVAPS, IVAPS), and complexity increased with 
the addition of auto-titrating expiratory positive airway 
pressure (EPAP), pressure support, and backup respira-
tory rate (BURR) [28–33]. Some devices also provide pre-
set modes for obstructive or restrictive disorders. These 
modes are the result of a very sophisticated engineering 
and technical research. They are not however “fail-safe.” 
None of these options has, to date, been proven superior 
to conventional titration of bi-level PPV [28, 32, 34–40]. 
They are at best “non-inferior” to individually titrated 
settings. They may have a favorable impact on time need-















Fig. 1. Mechanisms implicated in chronic 
hypercapnic respiratory failure.
Table 1. Most frequent indications for long-term ventilation
1. Obstructive lung disorders






3. Restrictive chest wall and parenchymal disorders other than 
obesity-hypoventilation
a. Kyphoscoliosis and other chest wall deformities
b. Ankylosing spondylitis
c. Chest trauma
d. Sequalae of tuberculosis and/or thoracoplasty and/or 
thoracic surgery for cancer
e. Restrictive pleural diseases
4. Neuromuscular disorders (see Table 4)
5. Sleep-related breathing disorders
a. Obstructive sleep apnea
b. Central sleep apnea
This table does not provide all indications for NIV: it lists the 
most frequent and common indications within the diagnostic 
categories provided.
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The SIG group recommends that the use of automat-
ed modes is left to the discretion of the clinician, with the 
following important caveats: 
• Automated modes are not presently recommended as 
a default option.
• Because most of these modes have not been indepen-
dently validated or proven to be superior to manual 
titration, the authors recommend having a low 
threshold for checking the adequacy of NIV by noc-
turnal polygraphy/polysomnography when using au-
tomated modes.
The authors also recommend using modes and de-
vices with which one is familiar, since performance of 
NIV devices is heterogeneous and devices have their spe-
cific algorithms.
1.5. Comments on Specific Ventilator Settings (Table 2)
Ramp or SoftStart options. Several devices for home 
NIV provide an option allowing a progressive increase in 
expiratory pressure values and, in some cases, of pressure 
support (PS = IPAP – EPAP). This “comfort option,” de-
rived from the ramp option commonly used for patients 
treated by CPAP for OSA, can be problematic in patients 
under NIV, and even a source of discomfort. If used re-
peatedly, it can also compromise the efficacy of ventila-
tion. In a recent case series highlighting the drawbacks of 
this option, the authors discourage the use of this option 
[41]. If used, initial pressure support should be at least 
5–6 cm H2O, time to attain set pressure should be as short 
as possible and relevance of this option should be regu-
larly reevaluated [41].
Pre-set decline of pressure support (Soft Stop, Ramp 
down). This option has been devised for patients with “de-
ventilation dyspnea” (i.e., severe transient dyspnea after in-
terruption of ventilation) although it has not been validated 
in independent clinical studies [42]. The ramp is triggered 
by the patient prior to his/her interruption of NIV: when 
activated, pressure support will decline progressively from 
its preset value to 0, over a predefined time (usually 10–20 
min). The ventilator then remains in a CPAP mode at EPAP 
value until it is stopped by the patient. 
Rise time. Figure 2 (top) shows how rise time impacts 
on pressurization. Short values decrease work of breath-
ing [43] but may be perceived as uncomfortable or cause 
leaks. In obstructive lung diseases, short rise times (≤150 
ms) favor a shorter inspiratory time (TI) and a favorable 
Table 2. Ventilator modes available on most devices used for home noninvasive ventilation (adapted from Schwarz and Bloch [23])
Abbreviation Mode Settings*
CPAP Continuous positive airway 
pressure
CPAP pressure with additional options according to manufacturer
PSV-S Pressure support ventilation, 
spontaneous mode
IPAP, EPAP, TIMIN, TIMAX, sensitivity of inspiratory and expiratory (cycling) 
triggers, inspiratory rise time, fall time
PSV-ST Pressure support ventilation, 
spontaneous/timed mode
IPAP, EPAP, respiratory back-up rate, TIMIN, TIMAX, or fixed TI**; sensitivity of 
inspiratory and expiratory (cycling) triggers, inspiratory rise time, fall time
PSV-T Pressure support ventilation, 
timed mode
IPAP, EPAP, respiratory frequency, TIMIN, TIMAX, or fixed TI, sensitivity of 
expiratory (cycling) trigger, inspiratory rise time, fall time
(a)PCV (Assisted) pressure control 
ventilation
IPAP, EPAP, respiratory frequency or respiratory back-up rate (in assisted 
mode), TI (TI:TE), sensitivity of inspiratory trigger (in assisted mode), 
inspiratory rise time, fall time
Automated modes
iVAPS, AVAPS Volume-assured pressure 
support ventilation
Targeted VT or VA; minimal and maximal pressure support, EPAP, and 
respiratory back-up rate
IPAP, inspiratory positive airway pressure; EPAP, expiratory positive airway pressure; TI, inspiratory time; TIMIN, minimal inspiratory 
time; TIMAX, maximal inspiratory time; TI, fixed inspiratory time; VT, tidal volume; VA, alveolar ventilation. Fall time refers to time set 
for passage from inspiratory to expiratory airway pressure (see Fig. 2, top). 
* Specific settings for modes described may not be available in all ventilators, depending on manufacturer and device. ** Options for 
inspiratory time (TI) settings depend on device and mode. Settings for TI may apply to patient-triggered cycles and/or controlled cycles. 
See text section 1.5. 
Long-Term Mechanical Ventilation: 



















































PIF: peak inspiratory flow
Cycling window
Fig. 2. Settings for bi-level positive pressure ventilation. PS, pres-
sure support (Δ[IPAP-EPAP]); IPAP, inspiratory positive airway 
pressure; EPAP, expiratory positive airway pressure; TIMIN, mini-
mal inspiratory time; TIMAX, maximal inspiratory time. Top: im-
pact of changes in rise time and fall time on pressurization. Bot-
tom: Cycling window. Cycling occurs between TIMIN and TIMAX. 





































































































Fig. 3. Cycling settings. PS: pressure support (Δ[IPAP-EPAP]). 
IPAP: inspiratory positive airway pressure; EPAP, expiratory pos-
itive airway pressure; PIF, peak inspiratory flow; PAW, airway pres-
sure. Impact of cycling criterion on pressurization and I:E ratio. A 
cycling criterion at a high percentage of PIF (top) favors a low I:E 
ratio, a longer expiration, and is appropriate in obstructive lung 
disorders. Conversely (bottom), a cycling criterion at a low per-
centage of PIF favors a higher I:E ratio, prolongs insufflation, and 
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I:E ratio (e.g., ≈ 1: 3). Conversely, rise times of 150–250 
ms are commonly used in restrictive lung diseases [4, 14, 
24]. Longer rise times may impinge on pressurization 
time and affect efficacy of ventilation. Values above 300 
ms are not recommended albeit for comfort reasons in a 
newly electively ventilated patient: this value should then 
progressively be decreased over time. 
Inspiratory trigger. In most devices used for long-term 
ventilation, inspiratory triggers are flow-dependent and 
very sensitive. Inspiratory trigger sensitivity scales vary 
according to device and manufacturer: they may be ex-
pressed as non-specific descriptors (i.e., high, medium, 
low), as arbitrary numerical units or as flow (L/min) re-
quired to trigger pressurization. Some devices provide al-
gorithms with automated settings (e.g., Autotrak®). In-
spiratory trigger sensitivity seldom requires adjusting 
and can be set by default at mid-range values. Increasing 
inspiratory trigger sensitivity may be an option in ad-
vanced NMD when inspiratory muscles are severely 
weakened (e.g., advanced ALS or Duchenne muscular 
dystrophy). In this situation, polygraphic tracings or de-
tailed analysis of ventilator curves may show patient-ven-
tilator asynchrony (e.g., unrewarded inspiratory efforts) 
[44]. The risk associated with increasing sensitivity is the 
occurrence of auto-triggering which may be a source of 
discomfort and affect ventilator efficacy. In case of unre-
warded inspiratory efforts, control of leaks and manage-
ment of intrinsic positive end-expiratory pressure (PEEPi) 
should be optimized before adjusting inspiratory trigger 
[44, 45]. PEEPi can be compensated by increasing EPAP 
values, and by optimizing the I:E ratio (decreasing TI and 
respiratory rate) and cycling criteria. 
Expiratory trigger (cycling). Expiratory trigger (or cy-
cling) setting is important for patient comfort, and pre-
vention of patient-ventilator asynchrony and dynamic 
hyperinflation in COPD [46]. It also contributes to im-
prove V/Q matching in severe restrictive disorders (e.g., 
obesity-hypoventilation). Bench tests have shown that 
home ventilators tend to cycle prematurely when submit-
ted to restrictive mechanics conditions, while delayed cy-
cling occurs with default settings in obstructive lung con-
ditions [47]. Cycling should be set at a high percentage of 
peak inspiratory flow (PIF) in obstructive lung diseases 
and at a low percentage of PIF in restrictive disorders 
such as obesity-hypoventilation (Fig. 3). The impact of 
cycling on the I:E ratio is illustrated in Figure 3. 
Inspiratory time. As mentioned in Table 2, options for 
TI settings vary considerably from one device to another 
and according to mode. TI may be either allowed to vary 
in a cycling window between a minimal (TIMIN) and max-
imal value (TIMAX) or set at a fixed value (Fig. 2, bottom). 
It may also be determined automatically by an algorithm. 
Some devices distinguish between controlled and trig-
gered cycles and apply TI settings only to one or the oth-
er. Clinicians must explore the specific options available 
on the device they are using. In all cases, TI must be above 
rise time [48]. A minimal value of 0.5 s is recommended.
Fall time (Fig. 2, top). A few ventilators allow to set the 
time required for pressure to drop from inspiratory to 
expiratory set values (i.e., cycling). Manufacturers sug-
gest that this may be used to prevent dynamic hyperinfla-
tion and to avoid premature expiratory closing of periph-
eral airways. This interesting option requires further clin-
ical validation. 
1.6. Humidifiers
Roughly 70% of patients on home NIV use heated hu-
midifiers (built-in or add-on) [4]. Humidification de-
creases dehydration of mucosal membranes, decreases 
upper airway resistance, and improves airway mucocili-
ary clearance [49, 50]. Although it does add some com-
plexity to the treatment, it is recommended to add active 
humidification with a low threshold. Use of distilled or 
demineralized water is recommended, with daily chang-
ing, and rinsing/washing of container. 
1.7. Tubings, Circuits and Filters
Respiratory circuits (i.e., the tubing between the ven-
tilator and the interface or tracheal canula) are either sin-
gle- or double-limb (Fig. 4).
Double-limb circuits are mostly used in acute care set-
tings (ICU) [23, 51]. One tube is for inspiration, the oth-
er for expiration. Active unidirectional valves redirect ex-
haled air through the expiratory circuit towards the res-
pirator thus avoiding any risk of rebreathing. These cir-
cuits (and associated interfaces) are non-vented (i.e., 
without exhalation port). A minimal expiratory flow 
(PEEP or EPAP) is not required to prevent CO2 rebreath-
ing, and thus PEEP can be set at 0. Double-limb circuits 
allow direct measurement of expired volume (VE). Inspi-
ratory and expiratory tubes may be coaxial: this allows 
passive heating of the inspired gas by expiratory flow. 
For home ventilation, single-limb circuits are most 
commonly used [23, 51]. They are less cumbersome. To 
prevent CO2 rebreathing, the circuit must have either an 
active expiratory valve, placed close to the mask to mini-
mize dead space, or a passive calibrated exhalation port 
(i.e., a passive leak valve) which can be either integrated 
in the interface (vented mask) or in the circuit (vented 
circuit). The active valve opens only during expiration. 
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The passive port creates an intentional continuous air 
leakage and requires a minimal expiratory pressure (usu-
ally 3–4 cm H2O) to prevent rebreathing and flush the 
CO2 from the circuit. Because of their ease of use, vented 
masks are most often used for home NIV. One disadvan-
tage of using a single-limb circuit is that unintentional 
leaks and tidal volume (VT) provided by ventilator soft-
ware are estimated and not measured. Bench studies have 
shown that VT (and therefore VE) is most often underes-
timated [52–54], with a high variability in bias reported 
(66–236 mL reported by Contal et al. [53]). In case of un-
intentional leaks, however, VT may be overestimated. 
The precision of the estimation of VT is not only influ-
enced by unintentional leaks but also by the breathing 
pattern and the underlying lung mechanics: in one bench-
test study, underestimation was more important in ob-
structive than in restrictive settings [52]. This may inter-
fere not only with monitoring of VT but also with the 
performance of ventilators in volume-targeted modes 
[52]. 
Mouthpiece ventilation (MPV: most often used for 
daytime ventilation in neuromuscular disorders) can be 
provided with a single or a double-limb circuit and vari-
ous types of mouthpieces [55–57]. Articulated support 
arms which can be fixed to wheelchairs are commercial-
ized and allow easy positioning of mouthpiece. Recent 
multimodal ventilators provide either volume-cycled or 
pressure-cycled dedicated modes for MPV, and do not 
require exhalation valves.
Heated tubings may improve patient comfort and ef-
ficacy of NIV when using a heated humidifier. Although 
heated and humidified air can improve airway mucocili-
ary clearance, management of secretions, and decrease 























Fig. 4. Tubings. a Double-limb circuit with unidirectional valve to avoid rebreathing, non-vented mask, and ex-
piratory valve built in the ventilator. b Single-limb circuit with active expiratory valve and non-vented mask. 
c Single-limb circuit with passive exhalation port (on tubing, close to non-vented mask). d Single-limb circuit 
with passive exhalation port incorporated into vented mask. e Coaxial tubing, unvented mask, and expiratory 
valve built in the ventilator.
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tient-ventilator asynchrony, and interfere with pressur-
ization [50]. Heated tubings prevent condensation that 
may occur when using a heated humidifier. A tissue hose 
around the tubing can also decrease the temperature gra-
dient and prevent condensation in ventilator tubing. 
Antibacterial filters are recommended when using the 
same ventilator for different patients (hospital setting). 
For home NIV, there is no formal recommendation as to 
their use. Heat- and moisture-exchanging filters may pre-
vent mucosal dryness when the use of an electrically heat-
ed humidifier is not feasible, such as during travel or am-
bulation.
Supplemental oxygen is provided by an oxygen blender 
in most hospital (ICU) ventilators. For home NIV, oxy-
gen is added to the breathing circuit when needed. In this 
setting, effective oxygen delivery and FiO2 depend not 
only on oxygen flow but also on intentional and uninten-
tional leaks, site of oxygen administration on ventilator 
circuit, site of exhalation port, ventilator settings and re-
spiratory drive [58]. There is thus no simple relation be-
tween oxygen requirements at rest without NIV and oxy-
gen flow required on the ventilator circuit, and titration 
of oxygen flow requires monitoring of SpO2. When the 
circuit is vented, the highest oxygen concentration is 
achieved with oxygen added to the mask: this may be rel-
evant in rare situations of very high FiO2 requirements 
[58]. In other cases, the most appropriate site of oxygen 
adjunction is close to the ventilator, which improves 
comfort. Certain homecare ventilators have a special oxy-
gen port for connection of the tubing from a low-pressure 
oxygen source such as an oxygen concentrator. This port 
closes automatically if the ventilator is turned off thereby 
preventing the risk of fire hazard by continuous oxygen 
flow into an inactive ventilator. Oxygen flow must be ti-
trated by pulse oximetry or arterial blood gas analysis.
Aerosols can be delivered during NIV. With a single-
limb circuit, vibrating mesh nebulizers are more efficient 
than jet nebulizers. They must be placed as close as pos-
a b c
d e f
Fig. 5. Interfaces for noninvasive ventilation. a Oro-nasal mask. b, c Nasal masks. d Facial mask. e Detail of ex-
halation valve of mask. f Mouthpiece. From Schwarz and Bloch [23].
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sible to the mask, between the mask and the exhalation 
port [59, 60].
1.8. Interfaces
The number of interfaces made available by the industry 
is constantly increasing, providing more and more options 
for improving patient comfort. It is important to work with 
healthcare providers or healthcare workers who are up to 
date with the most recent interfaces. At present, facial masks 
are the most widely used in published data concerning 
long-term NIV [4, 61–63]. However, there is an increasing 
awareness of the caveats associated with facial masks, that 
is, an increase in upper airway resistance caused by retro-
pulsion of the jaw, which may induce or prevent the correc-
tion of upper airway obstruction [25]. Oro-nasal masks 
(Fig. 5) are being increasingly used, are less cumbersome, 
and may be an alternative to facial masks either because of 
pressure sores on the nose or claustrophobia. Although na-
sal masks may favor mouth leaks during the night, this can 
be at least partially prevented by the use of chin straps that 
secure the position of the jaw although they cannot prevent 
leaks at the lips. Nasal prongs are a useful option for day-
time ventilation, for situations requiring low pressure sup-
port, although they may tolerate up to 25 cm H2O of inspi-
ratory pressure. Mouthpiece ventilation is also an excellent 
option for daytime ventilation in NMD. Custom-made 
masks are seldom required. 
Hygiene of masks is critical, is important for preven-
tion of skin lesions and leaks and requires repeated edu-
cation for patients and caregivers. All parts of the mask, 
especially the cushion and the ventilation port (exhala-
tion valve), should be cleaned after each use with luke-
warm water and mild soap. 
1.9. Where, How and by Whom Should Home NIV Be 
Implemented and Followed?
In Switzerland, long-term HMV, irrespective of the di-
agnosis or setting, must be prescribed by a certified pul-
monologist who can initiate the treatment and provide 
appropriate instruction to the patient and caregivers. The 
indication for HMV is usually reviewed by the medical 
advisor of the medical insurance.
Data from the GLS provide an indication as to actual 
practices in Switzerland for home NIV [4], which may 
evolve.
• Half of all long-term NIV treatments are started elec-
tively, and half in an emergency setting. 
• Roughly 80% of all patients start their treatment as in-
patients (electively or after an acute exacerbation). 
• On a long-term basis, in the GLS study, 1/3 of all pa-
tients were followed exclusively by a pulmonologist in 
private practice. Thus 2/3 of long-term NIV patients 
were followed by a hospital with or without a pulmo-
nologist in private practice. 
The role of healthcare providers and pulmonologists in 
private practice as actors in home NIV is increasing in Swit-
zerland. This practice differs from that of several European 
countries. In the Netherlands, in Germany, in Denmark, or 
in Norway for instance, patients on long-term NIV are 
treated and followed exclusively by expert hospitals. 
The SIG suggests the following recommendations:
• The goal of NIV is to improve symptoms and health-
related quality of life, decrease hospital admissions, 
correct hypoventilation, and optimize SpO2 to im-
prove survival, prevent cardiovascular complications 
such as pulmonary hypertension and cor pulmonale. 
If nocturnal PtcCO2 and sleep-related breathing dis-
orders (SRBD) are controlled, but SpO2 remains low, 
addition of oxygen on the ventilator circuit may be 
considered. 
• Elective implementation of NIV may be performed in 
a hospital, in an outpatient clinic, or at the patient’s 
home by an experienced team (healthcare provider) 
led by an experienced pulmonologist [64, 65].
• Outpatient initiation of NIV is a possible option in 
stable patients. It can be recommended for example 
in patients with a prior experience of CPAP, and in 
elective situations of patients with SRBD, OHS, or 
NMD, with monitoring of blood pressure and SpO2 
under NIV and follow-up of arterial or transcutane-
ous CO2 (PtcCO2). 
• Frequency of follow-up evaluations (modalities, tim-
ing) depends on the underlying pathology, and is usu-
ally performed every 3–12 months. A follow-up eval-
uation is in most cases recommended at least once a 
year. 
• Modalities of follow-up have been reviewed in detail 
by the SomnoNIV group (see Fig. 6) [66] and include 
clinical examination, targeted medical history, arte-
rial blood gases (ABG), nocturnal pulse oximetry, 
downloading and analysis of ventilator software, 
and, when indicated, more detailed sleep studies or 
lung function tests. 
• When available, use of nocturnal transcutaneous 
CO2 measurement is recommended, preferably at the 
patient’s home, especially in subjects under oxygen 
therapy or with persistent diurnal hypercapnia [66–
68]. 
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1.10. Tools for Measuring ABG
Correction of ABG and more specifically, of diurnal 
and nocturnal PaCO2 and respiratory acidosis, is one of 
the main goals of long-term mechanical ventilation. Mea-
surement of daytime ABG, most often through puncture 
of the radial artery, is considered as a gold standard pro-
cedure. However, it has its drawbacks: it may be painful, 
awakens the patient if performed at night, and requires 
expertise. Furthermore, it is only representative of the mo-
ment when sampling was performed and does not actu-
ally reflect the time course of PaCO2 during the night [66]. 
Alternative tools may provide useful information as to 
ABG while decreasing patient discomfort.
• Capillary arterialized samples are usually taken at the 
earlobe after application of a vasodilating gel. They 
have been reported as reliable for pH and PaCO2, with 
only small biases and limits of agreement in patients 
with various pulmonary disorders and in a meta-anal-
ysis [69, 70]. Results for PaO2 are less reliable, with an 
overall underestimation of arterial PaO2 by the capil-
lary technique [69, 71]. Capillary samples require fur-
ther validation in a population of subjects with CHRF 
[72, 73].
• End-tidal CO2: Although routinely used by anesthe-
tists during surgical procedures, the reliability of 
ETCO2 as a surrogate of ABG is insufficient. ETCO2 
systematically underestimates PaCO2. Agreement be-
tween PaCO2 and ETCO2 values is affected by V/Q 
mismatch, by physiological dead space, by pulmonary 
vascular disorders and by ventilatory mode (expira-
tion time) and thus values provided by ETCO2 are 
considered unreliable in adult populations [74]. It 
must be emphasized that a normal ETCO2 does not 
exclude hypercapnia, whereas a high ETCO2 is strong-
ly suggestive of hypercapnia, although it may underes-
timate its severity [66, 74]. The SIG suggests limiting 
the use of ETCO2 to special situations, for example, for 
children with NMD. 
• Transcutaneous capnography (PtcCO2): PtcCO2 mea-
surements are presently considered reliable in hemo-
dynamically stable patients and use of PtcCO2 devices 
has improved in user-friendliness. Devices are non-
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Detection of non-intentional leaks
(clinically and/or by NIV software)
 Clinical improvement and reduction in daytime PaCO2
 Mean nocturnal SpO2 > 90% more than 90% of recording time, without
   residual SpO2 oscillations
 Synthesis report from NIV software  showing more than 4 h/night of use,
  without discomfort (i.e., fragmented or multiple short periods on
   ventilator use)
 Correction of nocturnal hypoventilation documented by PtcCO2
  (if available)
Goals to be achieved in patient under NIV:
Fig. 6. Proposed algorithm for monitoring patients under long-term NIV. Adapted from Janssens et al. [66].
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invasive, and well tolerated at a probe temperature of 
42  ° C for 8–12 h [75]. Recent studies have reviewed the 
performances of several devices and shown that they 
have acceptable biases and limits of agreement, when 
compared to ABG, in patients with CHRF treated by 
long-term mechanical ventilation [67]. There are how-
ever a few limitations that the clinician must bear in 
mind: (1) there is a lag time between changes in PaCO2 
and PtcCO2 of a few minutes which makes these de-
vices unreliable for the detection of rapid changes in 
PaCO2 such as in OSA [76]; (2) most clinical studies 
show the occurrence of unpredictable errand values 
which require experience in tracing analysis and may 
be misleading [66]; (3) in spite of their apparent ease 
of use, PtcCO2 devices require a dedicated team with 
expertise: the number of unreliable traces increases 
when recordings are not organized by an experienced 
team. 
• The question of defining what is an acceptable defini-
tion of nocturnal hypoventilation has been arbitrarily 
solved by expert-based suggestions published by the 
American Association of Sleep Medicine [77]. This 
subject is however still open to discussion, and minor 
changes in definitions of hypoventilation can have a 
substantial impact in clinical practice [78, 79]. 
1.11. Frequent Side Effects of Mechanical Ventilation 
and Their Management
On average, NIV is remarkably well tolerated. Adher-
ence to treatment documented in recent Swiss studies, 
suggests that side effects are rarely important enough to 
compromise the pursuit of the treatment [4, 24]. 
A symptom-based pragmatic 11-item questionnaire 
targeting NIV-related discomfort has been recently made 
available for clinical practice (S3-NIV questionnaire) 
[80]. 
Table 3 lists the most frequent side effects reported on 
NIV. Appropriate humidification and management of 
leaks are necessary to correct most causes of discomfort. 
Repeated education for the patient and caregivers to 
avoid skin lesions and ensure appropriate positioning of 
the interface are crucial. Settings must be adjusted to lim-
it leaks and/or prevent abdominal distention and discom-
fort (i.e., rise time, level of pressure support, cycling cri-
terion...). 
A distressing symptom, referred to as “deventilation 
dyspnea,” is the occurrence of severe dyspnea for minutes 
to hours after cessation of NIV. This is reported in severe 
COPD [42] but also in neuromuscular disorders or in 
obesity-hypoventilation. Specific strategies have been 
suggested for COPD: in these patients, deventilation dys-
pnea may result from progressive dynamic hyperinflation 
overnight [42]. Mechanisms involved in OHS or neuro-
muscular disorders are not described. Several home ven-
tilators provide an option of progressive decrease in pres-
sure support before cessation of NIV, triggered by the pa-
tient, which warrants further clinical testing. 
Side effects related to invasive ventilation are discussed 
in section 7.4.
2. Obstructive Lung Diseases
2.1. General Comments
Although practices vary widely from one country to 
another, COPD is either the most frequent or among the 
most frequent indications for long-term NIV in most Eu-
ropean countries and represents on average 30% of the 
long-term NIV population [81, 82]. Acute exacerbation of 
COPD is the main cause of acute hypercapnic failure re-
quiring ventilatory support in the ICU: 44% of these pa-
tients are overweight or obese, and average BMI is 29.8 ± 
8.8 kg/m2 [83]. In France, data from the multicentric 
French ANTADIR observatory (www.antadir.org; cover-
ing ≈ 7,000 patients under NIV, 2011) document COPD 
as the second indication for NIV after SRBD. A recent 
Swiss descriptive study (GLS) showed that, among 489 
stable patients on NIV in the cantons of Geneva and Vaud, 
190 (39%) had COPD. Median BMI was 28 kg/m2 (IQR 
21; 33) for COPD patients without OSA (n = 135), and 32 
Table 3. Most frequently reported side effects related to the use of 
noninvasive ventilation
Patient discomfort resulting from:
– unintentional leaks (around the interface or through the 
mouth)
– leak-induced xerostomia, xerophtalmia or conjunctival irrita-
tion
– pain caused by head gear or mask
– skin lesions, pressure sores and ulcerations
– nasal obstruction, congestion, rhinorrhea, nasal mucosal 
dryness
– inappropriate alarm settings 
– abdominal distention 
– perceived patient-ventilator asynchrony (delayed triggering, 
premature or delayed cycling, autotriggering...)
– disrupted sleep
– claustrophobia or anxiety related to interface
Adapted from Janssens et al. [251].
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kg/m2 (IQR 28; 40) for those with overlap syndrome (n = 
55). These data thus show that the dominant phenotype 
among COPD requiring long-term NIV in our area is a 
population of comorbid frequently overweight or obese 
patients, with, in one third of cases, associated OSA. This 
must be kept in mind when analyzing the available evi-
dence regarding long-term use of NIV in COPD.
Short-term studies have shown a benefit of so-called 
“high intensity NIV” (combining high IPAP values and 
high BURR) on pulmonary function tests (PFT), 6 min 
walk tests, ABG, V/Q ratio, and HRQoL when compared 
to low-intensity NIV [84–86], without any major nega-
tive impact on quality of sleep [87]. Noteworthy is the fact 
that high-pressure NIV may affect cardiac function and 
must be applied with caution in patients with chronic 
heart failure, and should thus be initiated under monitor-
ing in a hospital setting [88–90]. 
After decades of conflicting evidence regarding the 
long-term benefit and clinical impact of NIV in COPD 
[91–93], meta-analyses [94, 95], 3 recent randomized-
controlled studies [86, 96, 97], and the report of an ERS 
task force have provided a partial scientific basis for the 
long-term use of NIV in COPD [98].
In 2014, Struik et al. [94] published a systematic review 
and meta-analysis, covering data concerning 245 COPD 
patients from publications compiled up to 2012: using 
IPAP levels of at least 18 cm H2O, using NIV for at least 5 
h per night, and having a baseline PaCO2 of at least 55 mm 
Hg (7.3 kPa) were identified as factors predictive of an im-
provement in ABG [67].
An important Dutch randomized controlled study 
(RESCUE trial) included COPD patients who remained 
hypercapnic (PaCO2 > 6 kPa [45 mm Hg]) just after an 
acute episode of hypercapnic respiratory failure (AEH-
RF) [97]: 201 COPD patients hospitalized for AEHRF 
were randomized 48 h after termination of ventilator 
support to long-term NIV (n = 101; PaCO2: 59.3 ± 9 mm 
Hg [7.9 ± 1.2 kPa]; FEV1: 25.6 ± 7.8% predicted) vs. usu-
al care (n = 100; PaCO2: 57.7 ± 9.7 mm Hg [7.7 ± 1.3 kPa]; 
FEV1: 25.7 ± 8.6% predicted). Average BMI was < 25 kg/
m2 in both groups. One year later, the authors found no 
significant benefit of NIV on survival, hospital readmis-
sions or HRQL when compared to the control popula-
tion. Furthermore, PaCO2 decreased both in the NIV 
and in the control group. It was concluded that recover-
ing from an AEHRF is not per se a justification for long-
term NIV.
A British multicentric RCT (HOT-NIV trial) included 
116 COPD patients recovering from an AEHRF with 
persistent hypercapnia (PaCO2 > 53 mm Hg, 7.1 kPa) 2–4 
weeks following an acute hypercapnic exacerbation re-
quiring NIV [99]. Patients with a BMI > 35 kg/m2, OSA, 
or other causes of CRF (NMD, CWD) were excluded. 
Patients were randomized to home oxygen therapy 
Acute episode of hypercapnic
respiratory failure requiring
ventilatory support
PaCO2 > 6 kPa 48 h
after resolution of acidemia
Try weaning from NIV










(PaCO2 > 7 kPa; pH > 7.35)
stable clinical condition
Home NIV indicated
Ventilator settings must bring PaCO2 below 6.5 kPa
or cause a decrease of PaCO2
of more than 20% of baseline value
Yes
No
Fig. 7. Suggested algorithm for noninvasive ventilation (NIV) in COPD based on references [96, 97, 99].
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(HOT) versus HOT and high-intensity NIV. NIV in-
creased the time to hospital readmission by approxi-
mately 3 months (4.3 months [IQR 1.3–13.8] for HOT-
NIV vs. 1.4 months [IQR 0.5–3.9] for HOT) and reduced 
the likelihood of occurrence of the primary endpoint – 
readmission or death within 12 months – by ca. 50% (HR 
0.49 [95% CI 0.31–0.77, p = 0.002]). The number needed 
to treat to avoid one readmission or death in this spe-
cific population was 6. Adjunction of NIV to HOT ap-
pears therefore useful in non-obese, non-apneic COPD 
who remain hypercapnic 2–4 weeks after an AEHRF ep-
isode. 
For COPD patients in a stable clinical condition (more 
than 4 weeks after an AEHRF), a German and Austrian 
multicentric prospective RCT compared 102 patients 
treated by NIV (FEV1: 26 ± 11% predicted, BMI 24.8 kg/
m2, PaCO2: 58.5 ± 6 mm Hg [7.8 ± 0.8 kPa]) versus 93 on 
usual care (FEV1: 27 ± 9% predicted, BMI 24.5 kg/m2, 
PaCO2: 57.7 ± 5.2 mm Hg [7.7 ± 0.7 kPa]) [96]. Inclusion 
criteria were: having a PaCO2 of at least 7 kPa (52.5 mm 
Hg), and a pH > 7.35 before randomization. They were 
followed for 12 months. High-intensity NIV was adjusted 
to reduce PaCO2 below 48.7 mm Hg (6.5 kPa), or at least 
20% lower than the baseline value. In this specific popula-
tion, NIV significantly improved baseline PaCO2, HRQL, 
and survival (mortality was 33% in the control group and 
12% in the NIV group). It also reduced hospital admis-
sions. The number needed to treat to avoid one death by 
NIV in this setting was 5.
Based on this evidence and closely following the most 
recent guidelines published by an ERS task force on NIV in 
COPD, the SIG suggests the following recommendations 
(all conditional) [98] (Fig. 7):
• Long-term NIV should be used in chronic stable hyper-
capnic patients (PaCO2 > 7 kPa [52.5 mm Hg]) with 
severe COPD1. 
• Long-term NIV should be implemented after an AEH-
RF only if hypercapnia (PaCO2 > 7 kPa [52.5 mm Hg]) 
persists 2–4 weeks after the acute episode. 
• The potential benefit of long-term NIV for recurrent 
AERHF without persistent hypercapnia at 2-4 weeks re-
mains undetermined. 
• When implementing NIV in COPD patients with 
CHRF, settings should be adjusted to decrease PaCO2 
below 6.5 kPa (50 mm Hg) or reduce PaCO2 levels by 
more than 20% of baseline level. 
• When implementing NIV in COPD patients with 
CHRF, fixed PSV should be preferred to auto-titrating 
modes as first-choice mode. 
NIV may also be considered as a component of pallia-
tive care and symptomatic treatment of dyspnea in end-
stage COPD, irrespective of ABG and PFT [100]. Ventila-
tor settings then aim to improve patient comfort, alleviate 
dyspnea, and decrease air-trapping and work of breathing. 
Nota bene: Recent German national guidelines for 
NIV [10, 11] also include the following items as indica-
tions for NIV in COPD:
• Nocturnal hypercapnia with a PaCO2 > 55 mm Hg (7.3 
kPa) irrespective of daytime PaCO2.
• Mild nocturnal hypercapnia (46–50 mm Hg; 6.1–6.7 
kPa) and an increase in PtcCO2 ≥10 mm Hg (1.3 kPa) 
during sleep.
It is the opinion of the SIG that these indications are 
not sufficiently evidence-based to be recommended pres-
ently and require further evaluation. 
2.2. Ventilator Settings
The use of PSV-ST and an IPAP of at least 18 cm H2O 
is recommended [94], if tolerated. The use of a high BURR 
is a component of the “high intensity ventilation” strategy 
recommended by German guidelines [84, 85]. However, 
in a British 3-month randomized trial of “high pressure 
and high BURR” (IPAP 29 cm H2O, BURR: resting respi-
ratory rate – 2) versus “high pressure and low BURR 
(BURR: 6/min)” in 12 severe hypercapnic COPD, the 
high BURR component did not provide any additional 
benefit on ABG, nocturnal PtcCO2, or average daily use 
of NIV, raising a doubt as to the necessity of a high BURR 
[86]. Short rise times (Fig. 2, top; 100–150 ms) are sug-
gested to improve patient comfort and decrease work of 
breathing. Cycling criterion (Fig. 3, top) should be set at 
a high percentage of PIF, to allow time for expiration. As 
previously mentioned, several German studies have em-
phasized the benefit of high levels of pressure support 
(“high intensity NIV”) on PFT, symptoms, and correc-
tion of ABG [84–86]. Values of pressure support provid-
ed in the above-mentioned studies [96, 97, 99], as well as 
those reported in patients treated in Switzerland [4, 24], 
are in an intermediate zone with a satisfactory control of 
ABG (see online supplement; i.e., IPAP values of 18–25 
cm H2O). Values of PEEPi reported in stable severe 
COPD are in the 4–6 cm range [101, 102]. For patients 
with very severe airway obstruction, marked hyperinfla-
tion or hypercapnia, higher values of PEEPi must be an-
ticipated and EPAP values titrated accordingly (i.e., up to 
10 cm H2O). 
1The ERS task force suggests a threshold PaCO2 level of 6.7 kPa (50 mm Hg).
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Because of the high proportion of patients with associ-
ated OSA among COPD recovering from an AEHRF [83], 
respiratory polygraphy or polysomnography with Ptc-
CO2 monitoring are recommended in these patients, and/
or titration of EPAP considering the possibility of associ-
ated OSA. 
2.3. Obstructive Lung Diseases Other Than COPD
CHRF related to diffuse bronchiectasis (cystic fibrosis 
[CF]-related and non-CF related). There are no RCTs of 
long-term NIV for bronchiectases, whether CF-related or 
not. Diffuse bronchiectases are recognized as a historical 
indication for long-term ventilation [103]. Use of NIV in 
diffuse bronchiectases is however associated with a poor 
prognosis [104, 105]. Uncontrolled data suggest that NIV 
may reduce symptoms and hospital admissions in CHRF-
related to bronchiectasis [106–108]. In both CF-related 
and non-CF-related bronchiectasis, NIV may be used as 
a bridge to transplantation [109], and/or as an adjunct to 
airway clearance techniques and exercise training. For CF 
patients, 2 Cochrane reviews mention a short-term ben-
efit of NIV on airway clearance and ABG in uncontrolled 
studies but are inconclusive as to the impact on survival 
[110, 111].
Severe bronchiolitis obliterans as manifestation of pul-
monary graft versus host disease after stem cell transplan-
tation or as chronic lung allograft dysfunction after lung 
transplantation may lead to CHRF and require NIV, ei-
ther as a palliative treatment or as a bridge to transplanta-
tion. For these indications, no formal recommendations 
can be established, and the decision of implementing NIV 
must be taken by expert centers within a multidisciplinary 
management.
NIV may also be indicated as an adjunct to pulmonary 
rehabilitation in severe COPD, either during exercise 




OHS is defined as the association of obesity (BMI ≥ 30 
kg/m2), and daytime hypercapnia (PaCO2 ≥ 45 mm Hg 
[6.0 kPa]), in the absence of any other restrictive or ob-
structive respiratory condition associated with alveolar 
hypoventilation [118]. OSA is present in 80–90% of cases 
and must therefore systematically be sought for as soon 
as clinically feasible. In the obese population, hypercap-
nia is associated with a worse prognosis (higher mortality, 
higher rate of hospital readmission) [119]. NIV improves 
ABG, quality of sleep, and reduces risk of hospital read-
mission [120, 121].
Recent RCTs have clarified the respective roles of NIV 
and CPAP in OHS [63, 122–125]. The most important 
data come from the Spanish multicentric Pickwick study 
and from Australian RCTs. In 2008, Piper et al. [123] ran-
domized 36 moderately hypercapnic OHS patients to 
PSV versus CPAP: after 3 months there was no significant 
difference between groups as to improvement in ABG, 
HCO3, compliance, Epworth Sleepiness Scale (ESS), or 
HRQoL. However, patients with a daytime PaCO2 > 55 
mm Hg (7.3 kPa) and those with a nocturnal increase in 
PtcCO2 or important nocturnal hypoxemia had been ex-
cluded from this trial.
A short-term RCT showed that NIV improved ABG 
and SRBD in OHS [126]. It also improved respiratory 
drive [127]. 
The Pickwick study randomized 86 OHS patients 
(mean PaCO2 49 mm Hg [6.5 kPa]) without severe 
OSA to NIV (volume-assured PSV) versus usual care 
[124]. After 2 months, NIV was superior to usual care 
for control of PaCO2, HCO3, daytime sleepiness, and 
HRQoL. 
The same multicentric Spanish group randomized 221 
patients with OHS (BMI: 44 ± 7 kg/m2; mean PaCO2: 50 
mm Hg [6.7 kPa]) and severe OSA in 3 groups: NIV, 
CPAP, and usual care [63]. After 2 months, NIV provided 
a marginal benefit when compared to CPAP in terms of 
PaCO2 and HCO3, while both NIV and CPAP were supe-
rior to usual care. 6 min walking distance and FEV1 im-
proved only in the NIV group. A substantial proportion 
of stable patients with OHS and OSA normalized their 
ABG (PaCO2) when treated by CPAP alone and benefit 
was related to compliance. 
An important contribution was the Australian study 
by Howard et al. [122]. These authors randomized 57 pa-
tients with OHS (mean age: 54 years, mean BMI: 54.9 kg/
m2; PaCO2: 59.6 ± 13.8 mm Hg [7.9 ± 1.8 kPa]; AHI: 82 
± 45/h) to CPAP versus PSV: there was no difference in 
treatment failure (i.e., non-resolution or progression of 
hypercapnia) after 3 months. The most recent data from 
the Spanish Sleep Network group provide results of a 
long-term follow-up of 204 patients with OHS and severe 
OSA (average BMI: 43 kg/m2; baseline PaCO2: 60 mm Hg 
[8 kPa]; AHI: 68/h) followed for a median of 5 years, ran-
domized to volume-assured PSV versus CPAP: there was 
no difference between groups in terms of correction of 
ABG, number of hospitalization days or admissions, car-
diovascular events, systemic blood pressure, or survival 
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[125]. Therefore, it appears clearly that NIV is not always 
mandatory in stable OHS with associated severe OSA, 
and that these patients warrant a trial of CPAP. A recent 
consensus statement has been published by the American 
Thoracic Society [128]. 
Based on this evidence, the SIG suggests the following 
recommendations (Fig. 8): 
• For all OHS patients with an AEHRF, NIV is the rec-
ommended therapeutic option. 
• Within 3 months of an AEHRF attributed to OHS, a 
native sleep study should be considered. In the pres-
ence of severe OSA, a trial of CPAP is appropriate. In 
case of mild/moderate or no OSA, pursuit of NIV is 
recommended.
• For stable patients, when ABG confirm the clinical 
suspicion of OHS, a sleep study is performed. An ini-
tial trial of CPAP is recommended if severe OSA is 
present (Fig. 8).
• For stable patients on long-term NIV for OHS, a 
switch to CPAP may be considered after documenta-
tion of presence of severe OSA. 
In case of major weight loss (e.g., after successful bar-
iatric surgery), the indication for CPAP or NIV must be 
reevaluated: in some cases (but not all) nocturnal positive 
pressure treatment may be discontinued [129, 130]. It is 
mandatory that these patients be monitored on a regular 
basis (e.g., yearly) because of the possibility of partial or 
complete failure of bariatric surgery over time, with re-
currence of OHS/OSA [131, 132].
As mentioned in the general comments, OHS patients 
are frequently comorbid, and management of comorbid-
ities, screening for concomitant heart disease, integra-
tion in a weight loss program and/or orientation towards 
bariatric surgery, and rehabilitation are all important 
components of the management of these patients [133–
136]. 
3.2. Ventilator Settings and Persistent Hypoxemia
The American Association of Sleep Medicine (AASM) 
and several other groups recommend the systematic use 
of PSG (polysomnography) for titration of NIV in OHS 
[137]. This is however not realistic in most countries, be-
cause of the restricted availability of PSG and, sometimes, 
the lack of expertise of sleep centers in NIV titration 
[138]. The SIG does not consider PSG as mandatory for 
titration of NIV. Titration of NIV with PSG may reduce 
patient-ventilator asynchrony but does not impact on 
quality of sleep, ABG, or somnolence [139]. PSG or polyg-
raphy are however mandatory for diagnosing and quan-


















Fig. 8. Noninvasive ventilation (NIV) in 
obesity-hypoventilation syndrome. Sug-
gested algorithm. PSV, bi-level positive 
pressure ventilation; OSAHS, obstructive 
sleep apnea hypopnea syndrome; AHI, ap-
nea-hypopnea index. See text for explana-
tion.
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phy, whenever available, allows simultaneous assessment 
of the severity of nocturnal hypoventilation.
Once on positive pressure ventilation, a reasonable 
agreement between PSG and ventilator software determi-
nation of residual respiratory events has been document-
ed in OHS (although in a limited number of subjects, and 
with devices from only one manufacturer) and thus, in 
clinical practice, ODI and ventilator software AHI can be 
used to control ventilator settings in combination with 
arterial blood gas analyses [66, 140, 141]. If ODI and AHI 
provided by ventilator software provide discordant re-
sults, a polygraphy or PSG may be contributive to a better 
documentation of residual respiratory events. Relying on 
ventilator-provided AHI alone is not recommended: noc-
turnal pulse oximetry should be combined with analysis 
of ventilator software [66]. 
Default devices for OHS are PSV ventilators. Although 
some groups use an “S” mode as a default option [123], 
the SIG recommends an S/T mode (spontaneous/timed), 
with a BURR close to spontaneous RR or slightly above. 
Use of a spontaneous (S) mode in OHS may increase oc-
currence of central apneas or hypopneas [142]. Converse-
ly, a high BURR is associated with a better control of both 
central and obstructive residual events [142]. Some 
groups recommend PCV in severe OHS.
EPAP must be titrated to:
• control associated sleep-disordered breathing, 
• improve V/Q relationships and nocturnal SpO2, and 
• compensate for auto-PEEP which is also reported in 
OHS (due to closure of peripheral airways, reduced 
FRC and increased closing volume) [143–147]. 
Rise time should be preferably in the 150–250 ms 
range. Cycling criterion should favor a prolonged inspi-
ratory pressurization to improve the V/Q ratio and thus 
oxygenation (i.e., low percentage of PIF; Fig. 3, bottom). 
Persistent hypoxemia under NIV is an adverse prog-
nostic sign [148]. Therefore, pressure support aims to 
control not only daytime PaCO2 but also nocturnal Ptc-
CO2 and SpO2. Levels of EPAP and IPAP should be in-
creased as much as tolerated before adding oxygen on 
the ventilator circuit. If PtcCO2 is controlled, as well as 
AHI, but SpO2 remains low, addition of oxygen on ven-
tilator circuit may be considered [149]. There is no evi-
dence that this impacts on outcome, but it does not af-
fect PaCO2 and optimizing nocturnal SpO2 is a goal of 
NIV in all indications, mainly as a prevention of pulmo-
nary hypertension and cor pulmonale [149]. Worsening 
of hypoxemia under NIV related to right to left shunt 
through a patent foramen ovale has been reported [150]. 
Conversely, NIV, when effective on ABG and nocturnal 
SpO2, has a positive impact on pulmonary hypertension 
and LVEF [151]. 
For patients already familiar with CPAP (failures of 
CPAP), or patients diagnosed in a stable clinical state, ini-
tiating NIV on an outpatient basis is feasible and cur-
rently performed routinely by many centers or private 
practitioners [4]. 
Persistence of obstructive events may result from ei-
ther inappropriate settings (too low EPAP) or from the 
use of facial versus nasal masks [25, 152]. Several reports 
have documented that, for CPAP and NIV, facial masks 
may increase upper airway resistance by exerting a pres-
sure on the mandibula, and thus compromise upper air-
way permeability. If obstructive events persist despite 
maximal EPAP tolerated and use of a nasal mask, increas-
ing BURR has been shown to have a favorable impact on 
residual obstructive events [142].
The probability of daytime hypercapnia in OSA pa-
tients increases with BMI [153, 154]. However, there is no 
established classification of the severity of OHS according 
to BMI. A classification of severity of OHS has been sug-
gested based on daytime levels of PaCO2 in clinically sta-
ble patients (46–50 mm Hg [6.1–6.7 kPa]: mild; 51–55 
mm Hg [6.8–7.3 kPa]: moderate; ≥56 mm Hg [7.5 kPa]: 
severe) [155]. In this retrospective study, the probability 
of controlling daytime PaCO2 with CPAP decreased as 
severity of OHS increased. There was no mention how-
ever of whether failure of PSV could be predicted accord-
ing to severity of daytime hypercapnia. Pragmatically, al-
though not formally established, probability of failure of 
PSV appears higher in super obese subjects (defined as 
having a BMI ≥50 kg/m2). In this case, PCV or volumet-
ric ventilation with PEEP may be required. Auto-adjust-
ing PSV modes have not been shown to be superior to 
PSV-ST in “super-obese” subjects [33]. 
4. Restrictive Respiratory Diseases Other Than 
Obesity-Hypoventilation and NMD
Restrictive respiratory diseases (RLD) can be subdi-
vided according to the major underlying physio-patho-
logical disorder:
• RLD related to predominantly CWD, for example: ky-
phoscoliosis or other major chest wall deformities, an-
kylosing spondylitis, sequelae of chest trauma, or ma-
jor chest surgery.
• RLD related to mixed diseases, for example: sequelae 
of collapsotherapy – including thoracoplasty – for tu-
berculosis (presently mainly of historical interest).
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• RLD related to predominantly parenchymal diseases: 
end-stage interstitial lung diseases (e.g., sarcoidosis, usu-
al interstitial pneumonitis, hypersensitivity pneumoni-
tis, pneumoconiosis), lung cancer (primary or metastat-
ic) with or without lymphangitic carcinomatosis.
These entities lead to:
• A decrease in compliance of the respiratory system. 
• An increased work of breathing, and impaired respira-
tory mechanics (geometric changes with a negative 
impact on respiratory muscle function) in the case of 
CWD.
• A variable impact on gas exchange, with, in the case of 
end-stage parenchymal diseases, frequently severe hy-
poxemia.
• In some cases, a decrease in ventilatory response to 
CO2 [156].
There are no published RCTs for most of the disease 
groups mentioned above. Indication for NIV is based on 
observational studies [15, 157] showing a positive impact 
of NIV on HRQoL, hospital admissions, prevention of 
respiratory failure, endurance performance, and pulmo-
nary hemodynamics [157–167].
CWD is a recognized indication for NIV: the natural 
history of the disease, depending on the severity of the 
chest wall deformity, is a progression towards CHRF with 
dyspnea on exertion, then resting dyspnea, hypoxemia 
(related to V/Q mismatch and zones of atelectasis), and 
pulmonary hypertension leading to cor pulmonale [168]. 
Nocturnal hypoventilation precedes daytime hypercap-
nia, can be detected by PtcCO2, and is a prognostic factor 
for requirement of NIV within the following year [166]. 
NIV has been shown to be superior to LTOT in CWD, 
and is associated with an improved survival [169, 170]. 
Other studies have shown improvements in ABG, PFT, 
and HRQoL. There have been no new recommendations 
since the 1999 ACCP expert-based consensus statement 
[15].
The SIG recommends initiating long-term NIV for 
restrictive lung diseases in the presence of symptoms of 
hypercapnia (fatigue, dyspnea, morning headaches...) 
and at least one of the following physiological criteria:
Daytime hypercapnia (PaCO2 ≥45 mm Hg [6 kPa])
Nocturnal hypoventilation according to AASM crite-
ria, defined by Berry et al. [77]:
• PtcCO2 ≥55 mm Hg (7.3 kPa) for more than 10 min 
or
• An increase in PtcCO2 ≥10 mm Hg (1.3 kPa) com-
pared to awake supine value to a value exceeding 50 
mm Hg (6.7 kPa) for more than 10 min.
Nota bene. The criterion “SpO2 < 88% for more than 5 
min on nocturnal pulse-oximetry” mentioned in the 1999 
consensus statement has been deleted, because of its lack 
of specificity, and the increasing availability of PtcCO2 
recordings. 
4.1. Ventilator Settings
PSV in an S/T mode is the default approach. Values 
of EPAP are low, unless OSA is associated. Rise time 
should be preferably in the 150–250 ms range. Cycling 
criterion should be set to a low percentage of PIF (Fig. 3, 
bottom) to counteract the rapid decrease in inspiratory 
flow secondary to diminished chest compliance. Illus-
trative settings are provided in the online supplemen-
tary material. 
Severe decreases in chest wall and/or parenchymal 
compliance may require high levels of pressure support 
over time, and use of PCV or volume-cycled devices as 
CRF progresses must be considered. In some cases, if 
quality of life is preserved, invasive ventilation may be 
considered. 
Pulmonary rehabilitation has been reported as an ef-
ficient adjunct to long-term NIV in CWD [171].
5. Neuromuscular Disorders
5.1. General Comments and Caveats
• Neuromuscular disorders are a very heterogenous 
group of diseases, with a variable prognosis (see Table 
4 for most frequent indications for NIV in NMD). 
Each NMD has its own “agenda” as to the timing of the 
expected progression towards CHRF. Furthermore, 
within each NMD, this “agenda” is variable from case 
to case. Follow-up before NIV must be adapted ac-
cordingly.
• Dyspnea, and daytime hypercapnia are late events in 
the evolution of most NMD. Classical signs of respira-
tory failure such as tachypnea, recruitment of acces-
sory muscles, or “tirage” may be masked by the under-
lying neuromuscular impairment. NIV must be imple-
mented if possible before occurrence of daytime 
hypercapnia to prevent acute episodes of hypercapnic 
failure.
• Many NMD have systemic implications (cardiolog-
ic, digestive, endocrinologic, orthopedic…), and 
regular assessment by a multidisciplinary expert 
team is important. The frequency of follow-up con-
sultations depends on the underlying disorder. Mul-
tidisciplinary management has been shown to im-
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prove prognosis per se in motoneuron diseases 
[172–174]. Advanced care planning should be a 
component of multidisciplinary management in all 
NMD, and especially in rapidly progressive disor-
ders such as ALS.
• Treating NMD patients with NIV has socioeconomic 
implications and represents a high burden on families 
and caregivers. It is part of the management of these 
patients to ensure that they receive appropriate sup-
port by experienced social workers, that requests for 
devices such as (electric) wheel chairs, or communica-
tion devices are made in a timely fashion, and that 
home support is ensured so as to relieve the burden on 
families. The authors underline that management and 
home support of NMD patients should be improved in 
Switzerland and that appropriate funding should be 
provided and assured.
• Many NMD become clinically apparent in childhood 
or at adolescence, and patients and their families often 
have a multidisciplinary management follow-up by a 
pediatric team. Progressive and coordinated transition 
to the adult multidisciplinary disease management 
team must be carefully planned.
• In ALS, multidisciplinary management is associated 
with optimized timing of NIV. Even selected patients 
with bulbar dysfunction can derive benefit from NIV 
[175].
• Most of the evidence concerning NIV in NMD is based 
on observational studies [3, 104, 105, 165], albeit for 
ALS, for which an RCT with a small number of par-
ticipants clearly showed that NIV improved HRQoL 
and survival in non-bulbar patients [176]. The fact that 
HRQoL does not deteriorate in patients with Duch-
enne muscular dystrophy after initiation of NIV was 
also demonstrated by Kohler et al. [177]. 
5.2. Follow-Up before Implementing NIV
 − For all patients with NMD and a probability of evo-
lution towards hypercapnic respiratory failure, a 
regular follow-up is mandatory and should include 
clinical assessment, targeted medical history, spi-
rometry, vital capacity sitting and supine, sniff nasal 
inspiratory pressure and maximal inspiratory pres-
sure, cough peak flow, nocturnal pulse oximetry (or 
whenever possible, nocturnal PtcCO2), and daytime 
ABG. Nocturnal hypoventilation is predictive of re-
quirement for NIV within the following months 
[166]. 
 − Criteria proposed as threshold levels for imple-
menting NIV are variable according to the under-
lying disease. Also, agreement between different 
criteria is often moderate or poor. Most tests used 
for follow-up of respiratory function are collabora-
tion-dependent; their course over time may differ 
from one test to another [178, 179]. Bulbar dys-
function may also impair reproducibility of respi-
ratory function tests. A panel of functional tests per-
formed at regular intervals is therefore preferable to 
appreciate the degree of respiratory muscle impair-
ment [20, 180]. 
 − Frequency of follow-up depends on the underlying 
disorder and its expected progression (usually be-
tween 3 months and 1 year).
Table 4. Most frequent neuromuscular disorders associated with 
chronic alveolar hypoventilation
Myopathies and muscular dystrophies:
– Duchenne’s muscular dystrophy and Becker’s muscular 
dystrophy
– Myotonic muscular dystrophy (Steinert’s diseases)
– Limb girdle muscular dystrophy
– Congenital muscular dystrophies
– Metabolic myopathies (e.g., McArdle, Pompe, mitochondri-
al myopathies)
– Inflammatory myopathies (e.g., polymyositis/dermatomyo-
sitis)
Diseases of the muscular endplate
– Myasthenia gravis
– Paraneoplastic syndromes (e.g., Lambert-Eaton syndrome)
Motoneuron disorders
– Motoneuron diseases (e.g., Amyotrophic lateral sclerosis, 
Spinal muscular atrophies (type I–IV)
– Poliomyelitis and post-poliomyelitis syndrome
Diseases of brain stem and/or pyramidal tract
– Congenital or acquired central hypoventilation (Ondine’s 
syndrome)
– Traumatic spinal cord lesions
– Arnold-Chiari malformation and associated conditions
– Multiple sclerosis 
Polyneuropathies
– Post-ICU critical illness polyneuropathy and myopathy 
– Inflammatory neuropathies (e.g., Guillain-Barré) 
– Phrenic neuropathies
– Other axonal neuropathies (toxic or paraneoplastic)
This list does not provide all possible neuromuscular indications 
for NIV.
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The SIG considers as clinical indications for NIV in 
NMD the following items:
• Control of symptoms related to respiratory muscle 
weakness and/or sleep-related hypoventilation or 
SRBD are per se an indication for NIV (e.g., morning 
headaches and fatigue, orthopnea, resting dyspnea, 
severe recruitment of accessory muscles, unexplained 
weight loss), even in the absence of daytime hypercap-
nia [181–183]. 
• Presence of sleep-disordered breathing (especially 
OSA) represents an increase in work of breathing, ir-
respective of symptoms, and NIV (because these pa-
tients will progress to CHRF) or CPAP should be con-
sidered. 
Any one of the following are physiological indications 
for NIV in NMD:
• Daytime hypercapnia (PaCO2 ≥45 mm Hg [6 kPa]) 
or
• Daytime normocapnia with nocturnal hypoventila-
tion measured by PtcCO2 according to AASM criteria 
(because of a high risk of rapid progression to daytime 
hypercapnia):
PtcCO2 ≥55 mm Hg (7.3 kPa) for more than 10 min 
or
An increase in PtcCO2 ≥10 mm Hg (1.3 kPa) com-
pared to awake supine value to a value exceeding 50 
mm Hg (6.7 kPa) for more than 10 min.
• Vital capacity < 50% of predicted or sniff nasal inspi-
ratory pressure/maximal inspiratory pressure < 40 
cm H2O, especially in rapidly progressive NMD.
Comment: Metabolic alkalosis should suggest the 
possibility of nocturnal hypoventilation and should lead 
to specific investigations. Also, prevalence of nocturnal 
hypoventilation varies widely according to definitions 
provided [78].
5.3. Ventilator Settings
 − Some expert centers consider that NIV in NMD should 
be preferentially performed with volume-cycled devic-
es, and with alarms, because of the risk of prolonged 
central sleep apnea or hypopnea, and for the security of 
the patient. Over the past decades, however, there has 
been a drift towards the use of PSV in S/T mode as de-
fault approach, at least as an initial modality (see sec-
tion on highly dependent patients). Life support de-
vices provide all the necessary alarms for patient safety. 
 − In most NMD, compliance of the respiratory system is 
marginally affected if chest wall deformity is not severe 
and pressure support levels are generally low. 
 − EPAP values may become a factor of discomfort when 
respiratory muscles are severely affected, and should 
be kept at minimal values in the absence of SRBD. 
 − Inspiratory trigger settings may require adjustment 
(increase in sensitivity) as disease progresses. 
 − An “S” mode is not recommended as standard setting, 
but can be used for special situations (i.e., eating with 
NIV, mouthpiece ventilation). An S/T mode with a 
BURR close or slightly above spontaneous RR is stan-
dard. The authors suggest to titrate BURR so as to min-
imize percentage of cycles triggered by the patient, and 
thus minimize residual work of breathing (i.e., “cap-
ture” the patients’ spontaneous RR). 
 − Rise time is set according to patient comfort, usually 
150–250 ms. Higher values will significantly impinge 
on pressurization and should be used only exception-
ally. 
 − It is an unexplained but frequent observation that pa-
tients with NMD are often more comfortable when 
slightly hyperventilated. 
 − Patient-ventilator asynchrony may occur in NMD 
(mostly in motoneuron disease) as a consequence of 
paradoxical movements of the vocal cords which may 
compromise the efficacy of ventilation [184]. Strate-
gies to adapt ventilator settings have been proposed 
[25]. 
 − Adjunction of oxygen is seldom required in the ab-
sence of any underlying lung disorder. 
 − For many NMD, use of NIV will become necessary 
outside of the home (i.e., adapted to an electric wheel 
chair), requiring a built-in battery with prolonged au-
tonomy; also, use of interfaces such as mouthpieces 
may be useful: in this case, multimodal ventilators with 
performant built-in batteries and specific modes for 
mouthpiece ventilation are recommended [185]. 
When dependence to NIV reaches 16 h/day, having a 
back-up “life support-type” ventilator (i.e., a second 
device) is mandatory.
5.4. Interfaces in NMD
 − Mouthpiece ventilation must be considered in very 
dependent patients to facilitate speech and social 
contacts, and to provide ventilator support while on 
the move (electric wheelchair). Several ventilators 
presently provide a “mouthpiece” mode which facil-
itates implementation of mouthpiece ventilation 
[185].
 − Use of nasal pillows may also increase comfort during 
the daytime.
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 − Although there is a theoretical risk of aspiration when 
using facial masks in patients who cannot easily re-
move their interface, in clinical practice, facial masks 
are often the only way to control the frequently occur-
ring mouth leaks, and are therefore used regularly 
(56% of NMD cases in the GLS study) [4]. Auxiliary 
means to facilitate the removal of the mask by the pa-
tient (e.g., hand strap) should be then considered. The 
alternative – use of a chin strap and nasal mask – is a 
possible option. 
 − In 24-h NIV dependency, a common approach is to 
use an oro-nasal/face mask during sleep and nasal pil-
lows or a nasal mask during daytime.
5.5. Mechanical Insufflation/Exsufflation in NMD
Assessment of ability to cough must be performed sys-
tematically in all patients with NMD, and, if necessary, 
specific treatment must be implemented. 
MIE devices provide a mechanical assistance for pa-
tients with an impaired ability to cough. These devices 
can be used with a facial mask, a mouthpiece, or a trache-
ostomy cannula, in children or adults. With appropriate 
teaching, these devices can be used by non-professional 
caregivers, or sometimes by the patient alone. Training is 
usually provided at home or at the hospital/specialized 
center by experienced physiotherapists or respiratory 
therapists/nurses. Illustrative video supports can be eas-
ily downloaded from the internet, although they do not 
replace appropriate individualized training. 
Basically, MIE simulates the physiological cough pro-
cess by providing 3 phases: (a) an insufflation phase to 
increase lung capacity as close as possible to TLC and 
benefit from the elastic recoil of the respiratory system; 
(b) an inspiratory plateau which may be provided manu-
ally (to improve synchronization) or automated (to fa-
cilitate home treatment by non-professional caregivers); 
(c) an exsufflation phase: a negative pressure is applied to 
the airways, which, combined with the elastic recoil pres-
sure of the respiratory system, generates an expiratory 
flow which mobilizes secretions. Use of MIE can be com-
bined with manually assisted cough techniques to im-
prove efficacy [186, 187]. 
Nota bene. These recommendations will not describe 
techniques such as “glosso-pharyngeal breathing,” “air-
stacking,” manually assisted coughing or other tech-
niques to assist airway clearance. These techniques are 
part of the standard management of secretions and air-
way clearance in severe NMD [188, 189]. 
The SIG suggests the following recommendations for 
implementing the use of MIE (Fig. 9):
In all cases, clinical assessment is mandatory, and 
MIE devices may be considered as necessary irrespective 
of cough peak flow values. 
The indication for MIE is based on the inability to 
clear secretions in an effective manner (clinical assess-
ment) and measurements of the cough peak flow:
270 L/min: cough is probably efficient.
160–270 L/min: cough may be inefficient; it is man-
datory to instruct the patient and caregivers on appro-
priate assisted cough techniques and, if they fail, to eval-
uate MIE devices. 
< 160 L/min: spontaneous cough is most probably in-
efficient to clear secretions from the airways, and the use 
of assisted cough techniques is mandatory. If they fail or 
are not feasible, MIE devices are necessary.
Use of MIE should be encouraged on an outpatient 
basis in all patients with NMD, a decreased cough peak 
flow, and difficulties to clear their airways from secretions 
with assisted cough techniques. 
Training at home can be provided to caregivers and/or 
unexperienced healthcare workers by experienced phys-
iotherapists or respiratory therapists. Repeated interven-
tions for caregiver education may be necessary. 
MIE settings. A recent report from an expert center 
(Royal Brompton Hospital, UK) provided average set-
tings for MIE from 181 patients with NMD (130 adults, 
51 children; 156 with NIV, 8 with a tracheostomy) as well 
as an algorithm for establishing MIE settings [190]. Val-
ues reported for adults were (median; IQR): 28 cm H2O 
(25–30) for insufflation; –35 cm H2O (–32; –40) for exsuf-
flation; TI: 1.5 s (1.3–1.8); expiratory time: 2.0 s (1.5–2.4); 
pause: 1.5 s (1.3–2.0). Most patients used automated 
modes. Rarely, higher pressures may be required, when 
compliance of the respiratory system is markedly de-
creased (severe obesity, kyphoscoliosis), or in patients 
with a tracheostomy and a small canula, to overcome the 
additional airway resistance. Initiation is usually per-
formed with lower insufflation pressures (15–-20 cm 
H2O). Pressures are then increased gradually beginning 
with exsufflation pressures [186, 187].
In motoneuron disease, paradoxical movements of the 
vocal cords and closure of upper airways (adduction of 
aryepiglottic folds, retroflex movement of the epiglottis, 
closure of hypopharynx, backward movement of the 
tongue) during MIE may compromise its efficacy and re-
quire adapting (decreasing) pressure levels and using a 
manual mode [191]. This does not only occur in bulbar 
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onset patients. Susceptibility to MIE settings may also 
change over time. Inspiratory values are critical: in pa-
tients with motoneuron disease, higher cough peak flow 
values were obtained using insufflation pressures of 30 
versus 40 cm H2O [192]. Insufflation values may have to 
be decreased to 15 cm H2O, with asymmetrical settings 
for insufflation and exsufflation (i.e., maintaining higher 
exsufflation than insufflation pressures) [191]. Decreas-
ing insufflation pressures and flow combined with longer 
TIs may improve upper airway stability in these cases 
[193]. Triggering insufflation by the patient may also be 
effective to reduce closure of the upper airway. In experi-
enced centers, these events can be detected by transnasal 
video laryngoscopy [184, 191, 193, 194]. 
Patient information. An application for cell phones 
and tablets (Apple or Android) developed by the Geneva 
CeSLA team is available as freeware for ALS patients and 
caregivers (CeSLApp).
6. Sleep-Related Breathing Disorders
6.1. General Comments
For most SRBD, positive pressure treatment is provid-
ed either with CPAP, or adaptive servo-ventilation (ASV) 
[5, 195, 196].
SRBD is the 1st indication for NIV in the French AN-
TADIR observatory (www.antadir.org; ASV not includ-
ed). Conversely, in the GLS study, patients with SRBD 
represent only 9% of patients under NIV.
6.2. Indications
The SIG recommends NIV for SRBD in the following 
situations:
• OSA and failure of CPAP because of persistence of 
abnormal AHI/RDI/ODI, and/or poor tolerance 
and/or requirement of high pressures to control respi-
ratory events. In this indication, NIV can most often 
be implemented on an outpatient basis.
• Normo- or hypocapnic central sleep apnea. This in-
cludes Cheyne-Stokes breathing and other forms of 
periodic breathing. When CSA are either idiopath-
ic, induced by medication (e.g., opiates), or associ-
ated with neurological disorders (most often cere-
brovascular diseases), NIV using PSV-ST can be 
considered after failure of CPAP or ASV. ASV is 
slightly superior to PSV in opiate-induced CSA 
[197] and is more appropriate to avoid hyperventi-
lating these patients, which could aggravate the un-
derlying SRBD. 
• Hypercapnic central sleep apnea. This group includes 
CSA induced by medication (e.g., opiates) or associ-
ated with neurodegenerative diseases. In these set-
tings, titration of NIV must be monitored by respira-
tory polygraphy or polysomnography, with transcu-
taneous capnography. In certain NMD (namely 
ALS), care must be taken to avoid or control para-
doxical movements of vocal cords [25].
In case of cardiac dysfunction (LVEF ≤45%) and 
Cheyne-Stokes breathing, ASV is contra-indicated. Al-
ternative treatments must be discussed after optimiza-

















Efficacy of spontaneous cough may be insufficient:
consider use of mechanical insufflation/exsufflation  
Spontaneous cough inefficient:
use of mechanical insufflation/exsufflation and
other techniques of assisted cough are mandatory
Cough considered efficient
Fig. 9. Threshold levels for cough peak ex-
piratory flow for implementing mechanical 
insufflation/exsufflation. This must be 
combined with clinical evaluation of cough 
efficacy.
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tion of medical treatment of chronic heart failure (fixed 
pressure nCPAP, oxygen...) [198]. There is, however, no 
evidence against the use of NIV in this setting in hyper-
capnic patients. 
7. Special Situations
7.1. The Highly Dependent Patient
A small group of patients under long-term NIV will 
become severely or totally dependent of their ventilator 
support. In the recent GLS survey, 2% of all NIV patients 
used their ventilator more than 16 h/day. These patients 
have most often advanced NMD (ALS, Duchenne mus-
cular dystrophy...), very severe COPD or other causes of 
tetraplegia (post traumatic or not). 
The SIG group raises several issues of concern.
 (1) Security. Because an interruption of ventilator sup-
port for a few minutes or hours may in some cases be fatal, 
having at home one spare ventilator ready to use, plugged 
and charged, with the same settings, is mandatory. Both 
ventilators must belong to the “Life support” category of 
home ventilators. 
The French guidelines published by the “Haute Auto-
rité de Santé” (November 2012) recommend that all pa-
tients requiring the use of their ventilator for more than 
16 h/day be equipped with two “life support” home ven-
tilators. This is also the case in the German national 
guidelines for HMV [12] and is the usual practice of Brit-
ish and Belgian centers. 
The SIG authors recommend that a second (back-up) 
ventilator should be provided when daily use of NIV ex-
ceeds 16 h/day because: 
• Minor changes in respiratory status (i.e., lower or up-
per respiratory tract infection) can lead to total de-
pendence in a matter of hours or days. 
• Not having a second device available in this context 
can be a major risk in areas where rapid intervention 
at home is not available.
• Conversely, a second device is the best way to avoid 
unnecessary admissions to an emergency ward for 
purely technical reasons.
• Evolution towards a complete dependence on NIV is 
a matter of weeks or, at most, months in these patients.
Importantly, the second ventilator is contributive to 
improving the autonomy of the patient since it can be 
used for mouthpiece ventilation and/or on an electric 
wheelchair and/or in a separate part of the home.
(2) Autonomy. As mentioned above, use of a second 
ventilator allows having a device for an electric wheel-
chair, and/or for use with a mouthpiece, and/or for 
travelling. This can also be required in a home with 
stairs.
(3) Appropriate home support. For highly dependent 
patients, the NIV team must ensure that appropriate sup-
port is provided to caregivers, and that adaptations of 
home environment are organized when necessary. These 
patients usually require 24/24-h support 7 days/week, 
and financial support as well as trained care givers must 
be made available, irrespective of the financial situation 
of the patient’s family. Although this is the case in most 
EU countries, the financing of this support is not guaran-
teed in Switzerland, and funding must often be sought for 
via patient associations, or private foundations (e.g., Pro 
Infirmis).
In case of a medical or technical problem, a hotline 
must be available for the patient’s care givers and advance 
care directives must have been discussed and clarified. 
For patients travelling abroad – which is possible for 
severely dependent NMD patients for instance if appro-
priately planned – temporary allocation of an additional 
back-up ventilator may increase level of security when 
confronted to another health system and different health-
care providers. Local reference “hotline” numbers must 
be provided in case of technical problems.
7.2. NIV and Rehabilitation
NIV has 2 documented indications in pulmonary re-
habilitation. The first is to increase tolerance to exertion 
in severely limited patients (i.e., during or just after an 
ICU stay for acute exacerbation, or as a first step for a se-
verely limited and bed-ridden patient). In this indication, 
NIV may allow bed-ridden subjects to walk, or perform 
exercises on cycloergometers, thus potentially accelerat-
ing their recovery, although this is not formally demon-
strated [115, 164, 199–205]. This approach can also be 
provided at home for patients performing their exercises 
under supervision.
The second indication is as an add-on treatment, e.g. 
nocturnal NIV during a rehabilitation program, with 
benefits documented in hypercapnic COPD and ILD pa-
tients [206, 207]. 
NIV during exercise should be adapted by experienced 
chest therapists/physiotherapists according to patient 
comfort. Increasing pressure support is usually required, 
as well as EPAP to decrease dynamic hyperinflation in 
severe COPD [208]. Rise time and TIMIN must be adapted 
to the patient’s increase in respiratory rate. 
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7.3. NIV and Palliative Care
NIV is a possible option in palliative care, for example, 
for patients with advanced oncologic disorders, progres-
sive respiratory failure related to end-stage interstitial 
lung disease, or post stem-cell or solid organ bronchiolitis 
obliterans [209]. End-stage interstitial lung disease is of-
ten associated with severe dyspnea, and a major increase 
in work of breathing. Treatment, its timing, and settings 
are primarily symptom-based, and implementation must 
be performed by therapists experienced in NIV. Rate of 
failure of symptom control may be high [210, 211]. NIV 
must aim to improve symptom control, but not prolong 
unnecessary suffering or discomfort. Deciding when to 
withdraw NIV should be discussed with the patient and 
his/her close relatives before implementing NIV or inva-
sive ventilation. In diseases leading to impaired commu-
nication (such as ALS), and potentially to a locked-in syn-
drome, it is particularly important to clarify beforehand 
when ventilator support should be interrupted [212, 213]. 
Alternative treatments under clinical evaluation are 
high-flow, humidified oxygen, or CPAP.
7.4. Invasive HMV
7.4.1. Invasive Ventilation in Switzerland and Other 
Countries
Long-term positive pressure ventilation via tracheos-
tomy (TPPV) remains a valuable option for a subgroup 
of specifically selected patients. In a European survey, pa-
tients treated with TPPV represented 13% of the popula-
tion on long-term mechanical ventilation [82], with a 
wide variability from country to country. In a British 
study of all-cause mortality of 1,210 patients under HMV 
over a 10-year period, patients using TPPV represented 
12% of the deceased [214]. A similar proportion of TPPV 
in HMV has been reported in Canada [215]. Detailed data 
of non-hospitalized patients on TPPV in Switzerland are 
not available but figures are probably much lower. Among 
3,498 patients who started home ventilation between 
2016 and 2019, 48 (1.4%) patients were under TPPV (an-
nual report, Schweizerischer Verband der Krankenkas-
sen; SVK). In the GLS Study, 11 of the 500 patients under 
HMV (2.2%) were under TPPV, a number which has re-
mained stable over the past 20 years [4]. Patients with 
spinal cord injuries or chronic NMD who are 24h-venti-
lator-dependent represent the most important subpopu-
lation on TPPV.
7.4.2. Conditions in Which TPPV Is Used
TPPV may be initiated following invasive mechanical 
ventilation in the ICU due to acute or acute-on-chronic 
respiratory failure with subsequent weaning failure. In 
NMD with bulbar dysfunction or massive secretions, 
elective tracheotomy may be an option. In some centers, 
TPPV is routinely initiated when patients with NMD 
Table 5. Comparison of invasive and non-invasive long-term home ventilation
Invasive ventilation Non-invasive ventilation
Advantages – Suctioning of lower airway secretions facilitated
– Cuff inflation provides some protection against aspiration of 
secretions and foreign material
– Application of higher airway pressure feasible
– Quantitative monitoring of ventilation reliable
– Advanced alarm functions available
– Non-invasive 
– Convenient initiation and withdrawal, intermittent use
– Swallowing and speech not impaired
– Near-normal life when not on NIV, less stigmatization
– Independent usage
Disadvantages – Invasive procedure required
– Risk of tracheomalacia, tracheal stenosis, and bleeding
– Stigmatization of patient in daily life
– Speech and swallowing may be impaired
– Higher risk of lower airway infection
– Limited care facilities available
– Cooperation required
– Mask leaks common, in particular with high pressure support
– Risk of skin damage/pressure ulcers
– In patients requiring continuous or near-continuous ventilatory 
support, eating/drinking is problematic
– Airways are not protected
Suggested 
indications
– Severe, life-threatening ventilatory failure
– Failure of NIV
– Continuous ventilatory support (20 h/day) needed and not 
feasible via NIV
– Reliable alarms needed (life support)
– Severe bulbar dysfunction
– Fixed upper airway obstruction
– Severe hypersalivation and swallowing difficulties
– Intermittent, non-life-sustaining support needed
– Sleep-disordered breathing
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such as Duchenne’s muscular dystrophy (DMD) become 
ventilator dependent. However, 24-h NIV is also feasible 
and convenient for many DMD and other neuromuscular 
patients and is standard practice in many centers [216–
219]. The availability of NIV together with MIE (Cough 
assist) is likely to reduce the need for invasive ventilation. 
In rapidly progressing NMD such as motor neuron 
disease with bulbar dysfunction, the question of TPPV 
arises often and requires careful consideration [213]. The 
final decision is the patient’s, and a non-biased complete 
information to the patient and his/her caregivers should 
be provided well in advance. Items to be discussed in-
clude: expected burden for caregivers in case of 24-h 
home care, limited availability of nursing home beds, spe-
cific complications, possibility and modalities of with-
drawal from invasive ventilation and end-of-life care. 
Some institutions have published their concept of TPPV 
in motor neuron disease [213]. Recommendations and 
patient decisions are influenced by personal, cultural, and 
ethical aspects, and informed decisions in terms of prog-
nostic expectations as well as end-of-life-care should be 
made individually.
There is no robust evidence to support recommenda-
tions on indications of TPPV. However, Table 5 lists 
some points to be considered. 
7.4.3. Consequences of TPPV 
TPPV creates a major burden for caregivers in Swit-
zerland because options for long-term care of ventilator-
dependent tracheotomized patients outside the hospital 
are limited and financial support for qualified help at 
home is often insufficient. Healthcare costs for patients 
with chronic respiratory failure are far higher for invasive 
than for non-invasive ventilation [220]. Management of 
patients on invasive ventilation usually requires 24-h 
care. This burden is often left to the close family who has 
to be trained in tracheostomy care, airway clearance, and 
emergencies. Specific, formal lay person training pro-
grams exist for instance in France and Germany but not 
in Switzerland. Furthermore, long-term care institutions 
for this population are almost inexistent in Switzerland. 
However, for slowly progressive neuromuscular and 
chest wall disease, the Mathilde Escher Heim in Zurich is 
an example of a specialized care center where a large co-
hort of patients with muscular dystrophy or other NMD 
live and/or attend school and pursue a professional activ-
ity. 
Quality of life on long-term TPPV, implemented after 
careful preparation, may be good in patients with muscu-
lar dystrophy or CWD [177, 221, 222]. It may however be 
severely impaired in patients with unscheduled tracheos-
tomy after weaning failure in the ICU, for instance in 
COPD [223]. To improve quality of life, mobility is an 
important aspect for patients on TPPV. Therefore, 2 ven-
tilators, of which one is portable or attached to an electro-
wheelchair should be available. These ventilators must 
have built-in batteries that allow a safe mobility for sev-
eral hours.
TPPV is associated with the risk of specific complica-
tions such as life-threatening – although rare – tracheal 
bleeding, ventilator-associated pneumonia, obstructive 
mucus plugging or tracheal granuloma formation and 
stenosis that may increase morbidity and mortality com-
pared to NIV [224–226]. Data on outcomes of long-term 
tracheostomy ventilation come from cohort studies but 
have not been systematically analyzed and compared to 
NIV in a conclusive way [214, 215, 227, 228]. 
7.4.4. Practical Aspects
In general, TPPV patients and patients with an antici-
pated ventilator dependency should be managed in a spe-
cialized tertiary center by a multidisciplinary team. A 
specific knowledge of circuits, cannulas, humidifiers, 
ventilators, speech functions, and TPPV-associated com-
plications is mandatory. An overview on the topic has 
been published recently and is summarized here [23]. 
TPPV can be delivered via surgical tracheotomy or 
percutaneous dilatational tracheostomy (usually per-
formed in the ICU). Both techniques have specific com-
plications, that is, risk of instability during cannula ex-
change in the early phase and bleeding in case of percu-
taneous dilatational tracheostomy or an oversized lumen 
in case of surgical tracheotomy.
Cannula and cuff. Different cannula types are available 
(length, angle, diameter, flexible vs. rigid, with and with-
out cuff, fenestrated vs. closed) [189]. The choice of the 
right tracheal cannula size and length is important to 
avoid leakage and damage to the trachea. Regular change 
of the outer tracheal cannula should be performed, at 
least initially, by an experienced team. Typical intervals 
are 6–8 weeks but depend on the amount of secretions 
and other aspects (e.g., local pain). A replacement tra-
cheal cannula of the same size and of a smaller size should 
always be available. Inner cannulas are often changed sev-
eral times a day. An inflated cuff reduces the risk of aspi-
ration but cannot reliably protect from this complication. 
Conversely, an inflated cuff can cause pressure ulcers and 
compromise swallowing. It is recommended to apply a 
low cuff pressure that is periodically monitored, and to 
avoid permanent cuff inflation. 
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A tracheotomy affects swallowing and speech. In the 
initiation phase of TPPV, intensive training of laryngeal 
function and speech training while the cuff is deflated are 
important. Some patients with preserved bulbar function 
may not need a cuffed tracheal cannula or require TPPV 
with an inflated cuff only during sleep. 
When a cuff is inflated and seals the trachea properly, 
secretions cannot enter the lower airways. However, if pa-
tients cannot swallow secretions, they may accumulate 
above the cuff balloon. This results in desensitization of 
the cough reflex in the upper airway and larynx. A de-
flated cuff allows airflow towards the upper airway for 
speaking and coughing. It is important that the tracheal 
cannula chosen is thin enough to allow air passage to the 
upper airway while the cuff is deflated, especially during 
use of a one-way speech valve (Passy Muir® or similar 
valve). Application of a speech valve while the cuff is in-
flated can be life-threatening since only an inward flow is 
possible. 
If a fenestrated cannula is used, both a closed and a fe-
nestrated inner cannula must be available. When using 
the fenestrated inner cannula and a deflated cuff together 
with a speech valve, phonation is facilitated due to air 
flowing around the cannula and through the fenestration 
towards the larynx.
Circuits. Different circuits (single- vs. double-limb) 
are available for TPPV. Both a single-limb non-vented 
circuit with an exhalation valve (active circuit) or, less 
commonly, an intentional leak connector (passive cir-
cuit) and a double-limb circuit with separate inspiratory 
and expiratory limbs are available for TPPV [218]. Sepa-
rate in- and expiratory limbs allow a reliable quantitative 
monitoring of VT, minute ventilation, and leaks. How-
ever, a single-limb circuit is easier to handle. 
Ventilators. Different life-support ventilators are avail-
able for invasive HMV (online suppl. Table S1). As previ-
ously mentioned (section 7.1), 2 ventilators are manda-
tory for security reasons in highly dependent patients. 
Different settings for day- and night-time may be used. 
Pressure-controlled ventilation (PCV) or volume con-
trolled ventilation are more commonly used than PSV in 
TPPV [214]. A target-volume might be set in addition to 
pressure modes, but advantages of this have not been 
demonstrated so far. Specific alarms are available for in-
vasive ventilation with life-support ventilators. Notewor-
thy is the fact that VT and VE cannot be accurately mea-
sured when cuff is deflated (unintentional leak through 
upper airway): this impairs alarm functions.
Humidification. Heated humidification is standard in 
invasive HMV during the night to avoid desiccation of 
the airways and thus bleeding and obstruction with mu-
cus plugs. However, humidification is seldom feasible in 
patients who are mobile in a wheel-chair: in this situation 
heat- and moisture-exchanging filters are sufficient in 
most cases.
Suctioning and mechanical in-/exsufflation. Suction-
ing of the upper and lower airways is routinely performed 
in TPPV. Deep suctioning should be limited because of 
the risk of mucosal lesions. Chest physiotherapy (assisted 
cough techniques) and mechanical in-/exsufflation with 
a Cough assist are important adjunctive measures to mo-
bilize peripheral secretions towards the central airways.
7.4.5. Special Considerations in Spinal Cord Injuries
Spinal cord injuries affect the respiratory system 
through several mechanisms [229–233]:
 − Loss of control of respiratory muscles, even at low spi-
nal cord injury levels (affecting pelvic and abdominal 
muscles). 
 − Decreased chest wall compliance, which can progress 
after the initial lesion.
 − Altered central respiratory control and negative im-
pact of frequently used CNS suppressants (antispas-
modic and pain-relieving medications).
 − Diaphragm dysfunction (e.g., “paradoxical orthop-
nea”), because of abdominal distention (chronic obsti-
pation and intestinal dysautonomy) or increased in-
tra-abdominal pressure (spasticity) [234, 235].
 − Bronchial hyperreactivity in injuries above TH 6, due 
to sympathetic roots disconnection [236, 237].
 − SRBD [238, 239].
 − Impaired clearance of airway secretions.
Requirement for ventilatory support. For lesions at a 
level of C3 or above, initial invasive mechanical ventila-
tion is almost invariably required. A change to electro-
stimulation of the diaphragm (direct stimulation of the 
motor points of the diaphragm or by phrenic nerve stim-
ulation) has, in selected patients, some advantages in 
comparison to conventional mechanical ventilation even 
for long-term use [240, 241].
For lesions at C3 or below, the requirement for contin-
ued ventilatory support varies from case to case, and noc-
turnal NIV may be an option.
SRBD in spinal cord injury. Prevalence of SRBD in spi-
nal cord injury is 4–5 times that of the general population; 
it is higher in tetraplegics (60–90%) than in paraplegics 
(55%) [242–244]. OSA impairs HRQoL in tetraplegic 
subjects as well as cognitive function [245, 246]. Addi-
tional risk factors for SRBD in tetraplegics include nar-
rowing of the upper airways due to chirurgical proce-
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dures to stabilize the spine, hyperplasia of neck muscles, 
and loss of the stretching effect on upper airways due to 
decreased lung volumes [247, 248].
CPAP is the treatment of choice for para- and tetraple-
gic patients with OSA and no sign of hypoventilation. In 
higher spinal cord injury level, low pressures often suf-
fice. Higher pressures can lead to poor tolerance, espe-
cially in the presence of expiratory muscle weakness. In 
these cases, PSV therapy is an option.
Central sleep apnea syndromes, often due to medica-
tions, are not uncommon and are treated according to 
methods used in other patients with this disorder (CPAP, 
ASV, PSV).
Because chest wall compliance may decrease over time 
in tetraplegics and patients with high-level thoracic le-
sions, thus increasing work of breathing, alveolar hy-
poventilation may develop after the initial injury, and will 
appear initially during the night. Therefore, in the long-
term follow-up of patients with high-level spinal cord in-
jury, the risk of nocturnal hypoventilation must be con-
sidered. If nocturnal hypoventilation (with or without 
daytime hypoventilation) is confirmed, NIV is indicated 
usually with PSV devices in both PSV and PCV modes. 
In the presence of SRBD and suspicion of nocturnal 
hypoventilation, which are often combined, further 
workup should include a polygraphic study which is eas-
ier to undertake than a PSG in a sleep laboratory (sleep 
labs are seldom equipped and trained for spinal cord in-
jury patients), combined with continuous PtcCO2 re-
cording [249].
Specific aspects related to NIV in spinal cord injury. 
NIV in high-level tetraplegia is generally possible if used 
during the night and partially during the day. However, 
24-h non-invasive ventilation in tetraplegics is rare.
PCV and PSV modes are both used during the night. 
There are no studies comparing PSV to PCV modes in 
this population. Patient acceptance may be better with 
PCV modes especially in tetraplegics. If PSV modes are 
used, a backup frequency is mandatory because of fre-
quent central apneas. Mouthpiece ventilation on demand 
or nasal prongs can be used during mobilization on a 
wheelchair.
Careful choice of masks, and appropriate setting of 
alarms are crucial, together with a specific training of all 
caregivers. Safety of patients with limited or no capacity 
to handle their mask by themselves in routine or in an 
emergency must be anticipated. Therefore, hospitaliza-
tions are usually required to initiate NIV.
Importantly, pressure support requirements may 
change over time due to changes in chest mechanics: pa-
tients with a rather recent spinal cord injury often need 
lower pressures than patients with a stiffened thoracic 
cage years after the initial lesion.
In all patients with spinal cord injury and ventilatory 
support, a regular follow-up is required, initially at 3- to 
6-month intervals, and subsequently once or twice a year.
As in all ventilator-dependent patients, a second de-
vice is always necessary if daily requirement for ventila-
tory support is ≥16 h. This is also the case if the patient 
needs a ventilatory support during daytime while using 
an electric wheelchair, to enhance mobility and autono-
my. Indeed, ventilator settings in a sitting position may 
differ from those used supine, and repeated dismantling 
and reinstalling of ventilators on a wheelchair may cause 
a safety problem. In this case, a built-in battery with a suf-
ficient autonomy is necessary (“life support device”) and 
a supplementary battery may be required. 
7.4.6. Management of Airway Secretions and Use of 
MIE (see also section 5.5)
The success of any ventilatory support for all para- and 
tetraplegic patients depends on efficient coughing. Two 
components are important: (1) to reach a maximal inspi-
ratory capacity before coughing, and (2) to maximize 
peak cough flow. The first target can be reached by tech-
niques such as continuous training of the remaining in-
spiratory muscles, air stacking, glossopharyngeal breath-
ing, insufflation with a resuscitation bag, or use of a MIE 
device (or NIV if a MIE mode is available) [250]. The 
second goal can be reached by self-assisted cough tech-
niques while supine or sitting in a wheelchair, assisted 
cough techniques administered by caregivers, or with 
MIE. A target peak cough flow of > 270 L/min should be 
reached for cough to be efficient.
8. Transition between Acute Care and Home (or 
Long-Term Institution)
Success of long-term home NIV (or NIV in a heath 
care institution) depends on appropriate preparation and 
timing of the transition, anticipation of present and fu-
ture requirements in terms of environment and training 
of caregivers, and anticipation of disease progression. 
Providing appropriate psychological, social, and financial 
support for the family and caregivers is also of major im-
portance. 
A multidisciplinary assessment and preparation of the 
transition to home care is necessary to include all the pos-
sible aspects of patient management in his/her new envi-
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ronment. Practical teaching should be started early and 
performed throughout the hospital stay for caregivers 
and level of competence and understanding should be 
regularly assessed by the hospital team. A checklist may 
be useful to ensure coverage of all necessary tasks to be 
performed at home. 
As previously mentioned, for invasive ventilation, in 
neighboring countries, short certifying training sessions 
are organized covering all aspects of respiratory care. 
Availability of this type of training should be encouraged 
in Switzerland for patients on invasive ventilation and/or 
for severely dependent patients.
When a transfer is planned to another long-term med-
ical institution, training of the healthcare workers of this 
institution must be initiated as early as possible. Contacts 
must be encouraged to create bonds between the patient 
and his/her future caregivers. This is also important to 
decrease the level of stress and anxiety of the patient, his/
her close relatives, and among healthcare workers. Final-
ly, time is needed to ensure acquisition of the necessary 
competences. 
Evaluating the adequacy and ergonomics of the home 
environment, and, if necessary, performing the required 
changes, must be organized with the social workers, ergo-
therapists and physical therapists/physiotherapists. 
Goals for transition to home care are summarized in 
Table 6.
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Table 6. Goals for transition from hospital to home care (or insti-
tution)
– Ventilator settings must provide the best possible control of 
alveolar hypoventilation (monitored by PtcCO2 and/or ABG)
– Patient is stabilized, and comfortable with his/her home 
ventilator
– The patient or his/her caregivers are autonomous in putting 
on and taking off the mask and in maintenance of the 
equipment (cleaning, use of the humidifier, etc.) 
– Necessary home care is organized (intervention of nurses, 
other healthcare workers [HCWs], chest therapists, physical 
therapists, technical control of ventilator and other devices)
– Home caregivers have been trained for all technical tasks, and 
written support is provided
– Professional support can be reached 24 h/day and 7 days/
week to provide appropriate guidance
– When required, backup equipment is immediately available 
on site 
– Financial aspects are covered, and patient and/or his/her 
family are not exposed to a burden they cannot face
Home healthcare providers must ensure that:
– they have been extensively informed of all relevant items 
regarding patient and treatment before he/she is transferred
– all caregivers (GP, pulmonologist, chest therapist, etc..) are 
identified, and that all necessary contact information is in 
their possession
– they have enough qualified/trained HCWs to provide a high 
level of care with substitutes in case of leave absences, 
sickness leaves, etc.
– they offer a hotline for technical support 24/24 h 7/7 days
– they will provide regular feedback to the pulmonologist in 
charge, as well as results of tests agreed upon with the 
treating pulmonologist (i.e., pulse oximetry, data from 
ventilator software, transcutaneous capnography, etc.)
– HCWs within the Health Care Provider organization receive 
regular and structured training in the field of management of 
chronic respiratory failure
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